Univariate analysis
. | OS, 2 years, % (95% CI) . | P . | EFS, 2 years, % (95% CI) . | P . | Relapse, 2 years, % (95% CI) . | P . | TRM, 1 year, % (95% CI) . | P . |
|---|---|---|---|---|---|---|---|---|
| Age | .6 | .3 | .7 | .02 | ||||
| Younger than 50 years | 48 (24-72) | 43 (11-65) | 55 (31-79) | 5 (0-14) | ||||
| Older than 50 years | 45 (28-62) | 27 (11-43) | 62 (42-82) | 29 (16-42) | ||||
| Patient sex | .3 | .4 | .3 | .9 | ||||
| Female | 63 (44-82) | 37 (15-59) | 52 (27-77) | 20 (4-36) | ||||
| Male | 36 (18-54) | 28 (12-44) | 64 (45-83) | 22 (9-35) | ||||
| Status prior allograft | .07 | .07 | .05 | .9 | ||||
| Chemosensitive | 51 (31-71) | 37 (18-56) | 53 (29-77) | 24 (10-38) | ||||
| Chemorefractory | 41 (22-60) | 25 (7-43) | 69 (47-91) | 18 (5-31) | ||||
| Relapse after prior HD therapy | .09 | .06 | .02 | .9 | ||||
| Yes | 38 (21-55) | 21 (5-37) | 73 (53-93) | 23 (9-37) | ||||
| No | 57 (35-79) | 44 (24-64) | 45 (21-69) | 19 (5-33) | ||||
| Prior HD therapy | .005 | .04 | .03 | .2 | ||||
| At least 2 | 26 (4-48) | 14 (0-38) | 60 (33-87) | 35 (10-60) | ||||
| Fewer than 2 | 56 (40-72) | 35 (19-51) | 57 (34-75) | 18 (7-29) | ||||
| Prior radiotherapy | .2 | .4 | .9 | .04 | ||||
| Yes | 39 (21-57) | 33 (9-57) | 46 (15-77) | 43 (19-67) | ||||
| No | 53 (35-71) | 31 (13-49) | 63 (41-95) | 15 (4-26) | ||||
| β2-microglobulin level | .1 | .1 | .6 | .06 | ||||
| Less than 3 mg/dL | 46 (17-63) | 45 (21-69) | 47 (20-74) | 14 (0-28) | ||||
| Greater than 3 mg/dL | 36 (17-55) | 29 (11-47) | 47 (21-68) | 39 (20-58) | ||||
| Deletion 13q14 | .03 | .05 | <.001 | .4 | ||||
| Yes | 18 (0-38) | 18 (1-32) | 77 (57-97 | 18 (4-32) | ||||
| No | 67 (51-83) | 42 (24-60) | 44 (22-66) | 24 (10-38) | ||||
| IgA | 56 (27-85) | .8 | 24 (0-61) | .9 | 60 (13-100) | .9 | 29 (2-56) | .9 |
| Others | 46 (31-61) | 32 (16-48) | 60 (43-77) | 20 (9-31) | ||||
| Patient's CMV serostatus | .4 | .1 | .01 | .3 | ||||
| Positive | 54 (39-69) | 36 (20-52) | 53 (34-72) | 24 (12-36) | ||||
| Negative | 16 (0-43) | 13 (0-33) | 16 (0-41) | 16 (0-36) | ||||
| Donor's age | .08 | .2 | .4 | .4 | ||||
| Younger than 50 y | 28 (6-50) | 38 (20-56) | 48 (28-68) | 27 (11-43) | ||||
| Older than 50 y | 61 (35-87) | 38 (5-65) | 53 (22-84) | 17 (0-35) | ||||
| Donor's sex | .3 | .3 | .9 | .05 | ||||
| Female | 41 (19-63) | 21 (2-40) | 69 (44-94) | 35 (15-55) | ||||
| Male | 51 (34-68) | 38 (21-55) | 56 (36-76) | 12 (2-22) | ||||
| Transplantation | .1 | .4 | .9 | .3 | ||||
| MUD | 37 (15-59) | 16 (0-42) | 48 (21-75) | 27 (11-43) | ||||
| Related | 57 (41-73) | 33 (17-49) | 61 (43-79) | 17 (5-29) | ||||
| Cell dose CD34+ cells/kg BW | .6 | .9 | .5 | .2 | ||||
| Less than 5 × 106 cells | 49 (22-71) | 21 (0-45) | 75 (46-100) | 17 (0-35) | ||||
| Greater than 5 × 106 cells | 55 (39-71) | 38 (20-56) | 49 (27-71) | 28 (13-43) | ||||
| Acute GVHD grades II-IV | .7 | .8 | .6 | .3 | ||||
| Yes | 49 (27-71) | 37 (17-57) | 50 (25-75) | 24 (7-41) | ||||
| No | 48 (30-66) | 30 (12-48) | 66 (46-86) | 15 (4-26) | ||||
| Interval DX-TX | .7 | .5 | .6 | .7 | ||||
| Shorter than 2 y | 51 (31-71) | 32 (14-50) | 60 (38-82) | 19 (5-33) | ||||
| Longer than 2 y | 36 (17-55) | 22 (3-41) | 70 (46-94) | 24 (9-39) | ||||
| Chronic GVHD | .8 | .7 | .8 | .3 | ||||
| Yes | 58 (32-84) | 32 (17-47) | 63 (36-90) | 20 (10-30) | ||||
| No | 52 (33-71) | 40 (0-83) | 52 (33-71) | 40 (0-83) |
. | OS, 2 years, % (95% CI) . | P . | EFS, 2 years, % (95% CI) . | P . | Relapse, 2 years, % (95% CI) . | P . | TRM, 1 year, % (95% CI) . | P . |
|---|---|---|---|---|---|---|---|---|
| Age | .6 | .3 | .7 | .02 | ||||
| Younger than 50 years | 48 (24-72) | 43 (11-65) | 55 (31-79) | 5 (0-14) | ||||
| Older than 50 years | 45 (28-62) | 27 (11-43) | 62 (42-82) | 29 (16-42) | ||||
| Patient sex | .3 | .4 | .3 | .9 | ||||
| Female | 63 (44-82) | 37 (15-59) | 52 (27-77) | 20 (4-36) | ||||
| Male | 36 (18-54) | 28 (12-44) | 64 (45-83) | 22 (9-35) | ||||
| Status prior allograft | .07 | .07 | .05 | .9 | ||||
| Chemosensitive | 51 (31-71) | 37 (18-56) | 53 (29-77) | 24 (10-38) | ||||
| Chemorefractory | 41 (22-60) | 25 (7-43) | 69 (47-91) | 18 (5-31) | ||||
| Relapse after prior HD therapy | .09 | .06 | .02 | .9 | ||||
| Yes | 38 (21-55) | 21 (5-37) | 73 (53-93) | 23 (9-37) | ||||
| No | 57 (35-79) | 44 (24-64) | 45 (21-69) | 19 (5-33) | ||||
| Prior HD therapy | .005 | .04 | .03 | .2 | ||||
| At least 2 | 26 (4-48) | 14 (0-38) | 60 (33-87) | 35 (10-60) | ||||
| Fewer than 2 | 56 (40-72) | 35 (19-51) | 57 (34-75) | 18 (7-29) | ||||
| Prior radiotherapy | .2 | .4 | .9 | .04 | ||||
| Yes | 39 (21-57) | 33 (9-57) | 46 (15-77) | 43 (19-67) | ||||
| No | 53 (35-71) | 31 (13-49) | 63 (41-95) | 15 (4-26) | ||||
| β2-microglobulin level | .1 | .1 | .6 | .06 | ||||
| Less than 3 mg/dL | 46 (17-63) | 45 (21-69) | 47 (20-74) | 14 (0-28) | ||||
| Greater than 3 mg/dL | 36 (17-55) | 29 (11-47) | 47 (21-68) | 39 (20-58) | ||||
| Deletion 13q14 | .03 | .05 | <.001 | .4 | ||||
| Yes | 18 (0-38) | 18 (1-32) | 77 (57-97 | 18 (4-32) | ||||
| No | 67 (51-83) | 42 (24-60) | 44 (22-66) | 24 (10-38) | ||||
| IgA | 56 (27-85) | .8 | 24 (0-61) | .9 | 60 (13-100) | .9 | 29 (2-56) | .9 |
| Others | 46 (31-61) | 32 (16-48) | 60 (43-77) | 20 (9-31) | ||||
| Patient's CMV serostatus | .4 | .1 | .01 | .3 | ||||
| Positive | 54 (39-69) | 36 (20-52) | 53 (34-72) | 24 (12-36) | ||||
| Negative | 16 (0-43) | 13 (0-33) | 16 (0-41) | 16 (0-36) | ||||
| Donor's age | .08 | .2 | .4 | .4 | ||||
| Younger than 50 y | 28 (6-50) | 38 (20-56) | 48 (28-68) | 27 (11-43) | ||||
| Older than 50 y | 61 (35-87) | 38 (5-65) | 53 (22-84) | 17 (0-35) | ||||
| Donor's sex | .3 | .3 | .9 | .05 | ||||
| Female | 41 (19-63) | 21 (2-40) | 69 (44-94) | 35 (15-55) | ||||
| Male | 51 (34-68) | 38 (21-55) | 56 (36-76) | 12 (2-22) | ||||
| Transplantation | .1 | .4 | .9 | .3 | ||||
| MUD | 37 (15-59) | 16 (0-42) | 48 (21-75) | 27 (11-43) | ||||
| Related | 57 (41-73) | 33 (17-49) | 61 (43-79) | 17 (5-29) | ||||
| Cell dose CD34+ cells/kg BW | .6 | .9 | .5 | .2 | ||||
| Less than 5 × 106 cells | 49 (22-71) | 21 (0-45) | 75 (46-100) | 17 (0-35) | ||||
| Greater than 5 × 106 cells | 55 (39-71) | 38 (20-56) | 49 (27-71) | 28 (13-43) | ||||
| Acute GVHD grades II-IV | .7 | .8 | .6 | .3 | ||||
| Yes | 49 (27-71) | 37 (17-57) | 50 (25-75) | 24 (7-41) | ||||
| No | 48 (30-66) | 30 (12-48) | 66 (46-86) | 15 (4-26) | ||||
| Interval DX-TX | .7 | .5 | .6 | .7 | ||||
| Shorter than 2 y | 51 (31-71) | 32 (14-50) | 60 (38-82) | 19 (5-33) | ||||
| Longer than 2 y | 36 (17-55) | 22 (3-41) | 70 (46-94) | 24 (9-39) | ||||
| Chronic GVHD | .8 | .7 | .8 | .3 | ||||
| Yes | 58 (32-84) | 32 (17-47) | 63 (36-90) | 20 (10-30) | ||||
| No | 52 (33-71) | 40 (0-83) | 52 (33-71) | 40 (0-83) |
OS indicates overall survival; EFS, event-free survival; HD, high dose; MUD, matched unrelated donor; and DX-TX, time from diagnosis to transplantation.